

The Then, Now, and Future of the "Biotics" Family Speakers: Eamonn Quigley, Kristin Verbeke and Clara Belzer Chair: Dan Tancredi

Resurrect your memory and your imagination for this interactive session. Twenty years ago, there was no Nutrition and Health Claims legislation in the EU, the term microbiome had only just begun to be applied to our field, and ISAPP's first meeting was being convened in London Ontario. Today, microbial biotherapeutics are in development and use across the globe, companies want you to believe that they can pair gut microbiome tests with tailored probiotic recommendations, and the industry has grown into the billions of dollars. Postbiotics have entered our lexicon, the number of pro/prebiotic papers is now over 40,000.

What will tomorrow bring? 2022 marks ISAPP's 20th anniversary, prompting the opportunity for us to take a look back and forward for the 'Biotics' field. This session will feature three short talks from accomplished experts in the field, providing provocative insights into where we've been, were we are now, and what may be to come. After these talks, all meeting participants will be distributed among 12 tables to discuss aspects of these topics and then will report back 1 or 2 highlights from the discussion to the full group. So, think laterally and try to predict the future of the Biotics family 20 years from now.

Schedule: 13:45-15:30 (105 min)

13:45-13:55. Introduction. Dan Tancredi
13:55-14:05. *Then*. Eamonn Quigley
14:05-14:15. *Now*. Kristin Verbeke
14:15-14:25. *Future*. Clara Belzer
14:25-14:55. Table discussions – 12 tables of ~15 people
14:55-15:25. Table report backs (2-3 min/table)
15:25-15:30. Conclusion/Follow up. Dan Tancredi

Table leaders

Andrea Doolan, Atlantia Clinical Trials Ltd; Denis Guyonnet, Diana Nova; Irene Lenoir-Wijnkoop,
 Utrecht University; Zac Lewis, Synbiotic Health; Seema Mody, DSM; David Obis, Danone Nutricia
 Research; Mariya Petrova, Winclove Probiotics Company; Amanda Ramer-Tait, University of Nebraska;
 Delphine Saulnier, Novozymes; Marieke Schoemaker, FrieslandCampina; Elaine Vaughan, Sensus (Royal Cosun); Anisha Wijeyesekera, University of Reading

The table leader's task is to choose question(s) to discuss (see list below) with input from table members and encourage input from the 15 people around your table. After a 30-min discussion period, each table leader will report back to the full group with 2-3 key bullet points (2.5 min max). Table leaders will be asked to email the bullet points from your group to Dan Tancredi (djtancredi@ucdavis.edu) so he can capture the highlights for a meeting report or blog post.

Tables:

Twelve round tables will be marked for the discussion, each led by one of the pre-identified table leaders. About 170 total meeting participants, including 30 young scientists (SFA), are expected at the meeting. They will be asked to pull up chairs to join one of the 12 identified tables. Speakers will join a table of their choosing. The 30 SFA members will be asked to distribute among all the tables to add young scientist perspective. The 14 ISAPP board members should distribute among all tables, too.

Table Questions – each table can consider as many of these as it wants:

When the question states 'biotic', any one or several of them can be addressed

- 1. Looking back, what makes you happy about the past? What disappoints you? With hindsight, what would you do differently?
- 2. Looking forward, what clinical indications should be addressed by 'biotics' and why?
- 3. What has to happen in the next 5 years for the 'biotics' field to make a leap forward?
- 4. Looking forward, will we attain a precision 'biotic'? When? How will it work?
- 5. What will be considered essential measures (quantification, characterization, purity, microbiota readouts, health outcomes, etc) of a 'biotic'?
- 6. What should ISAPP do in the future to advance 'biotic' science?
- 7. What activities undertaken by other scientific, medical, regulatory, or trade associations/societies should ISAPP support/reinforce/amplify?